Admit (50mg) 14 Tablets

This medicine contains sitagliptin, an orally-active inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme, used as an oral hypoglycemic agent in Type II diabetes mellitus. Dipeptidyl peptidase-4 (DPP-4) is an enzyme that acts to inactivate glucagon like peptide-1(GLP-1). When sitagliptin inhibits DPP-4 then levels of GLP-1 will increase that results in increased insulin release from the body after taking meals and in this way glucose tolerance by the body will increase. For adult patients with type 2 diabetes mellitus, sitagliptin is indicated to improve glycemic control as an adjunct to diet and exercise. Used in patients that show inadequate glycemic control by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.

Tablet

Diabetes Type 2

Dose must be taken according to the doctor’s advice only; doses given below are suggested as supportive literature for better understanding in some areas of requirements. Adult dose: For diabetes type II: 100mg orally once daily. For patients with hemodialysis, peritoneal dialysis or severe renal improvement: 25mg orally once a day. The dose is 25, 50 or maximum 100mg sitagliptin daily. If taken in combination with other medicines then dose must be adjusted accordingly.

In case of overdose with Sitagliptin consult your doctor first, he may take the usual supportive measures, e.g., he may remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring and take supportive therapy as dictated by the patient's clinical status. Sitagliptin is modestly dialyzable. It is not known if Sitagliptin can be dialyzable by peritoneal dialysis or not.

In case you missed any dose, take the next dose as soon as you remember, but don't double your next dose to compensate for the missed one.

Take it orally as advised by the physician.

Do not use it in case of hypersensitivity to Sitagliptin. Not suitable for use in type I diabetes mellitus or for the treatment of diabetic ketoacidosis.

Hypersensitivity reactions Hypoglycemia Headache Dizziness Constipation Vomiting Acute Pancreatitis Pruritus Angioedema Rash Urticaria Cutaneous vasculitis Exfoliative skin conditions Myalgia Back pain Arthropathy.

After initiation of Sitagliptin, patients should be observed carefully for signs and symptoms of pancreatitis (inflammation of pancreas). If pancreatitis is suspected, Sitagliptin should promptly be discontinued and appropriate management should be initiated.

Store at 25°C. Protect from heat and moisture.